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Background
Description of the condition
Cystic Fibrosis (CF) is a multi-system, inherited, life-limiting disorder, which affects
approximately 10,000 people in the UK and 28,000 in the US 1,2. CF is caused by a
defect in the gene which codes for Cystic Fibrosis Transmembrane Conductance
Regulator (CFTR) – a protein which sits on epithelial cell surfaces and regulates
chloride transfer 3. There are many known mutations in the CF gene, with the most
common being p.Phe508del 4. CF is an autosomal recessive condition and it is
estimated that 1 in 25 of the UK population is a carrier for CF, having one defective
gene but being unaffected 5. Those with two defective copies of the CF gene (1 in
2500 live births in the UK 5) are unable to produce a functioning protein and
therefore have CF6. When the CFTR protein does not work properly, this leads to a
build-up of thick sticky mucus in the lungs, with recurrent and chronic pulmonary
infection, together with pancreatic insufficiency (in most patients). Figure 1 shows the
scope of systems affected by CF.
In the lung, the thick secretions lead to an inability for the normal mechanisms to
clear bronchial mucus and inhaled debris, resulting in conditions favourable for
bacteria to establish infection. Common bacterial infections in CF include
Pseudomonas aeruginosa, Staphylococcus aureus and Haemophilus influenzae
amongst others 7. Recurrent and chronic infection and inflammation leads to lasting
lung damage resulting in reduced lung function and eventually respiratory failure.
The use of multiple antibiotics over a lifetime of exposure may lead to clinically
important, cumulative side effects in people with CF. Renal and ototoxicity caused by
aminoglycosides can cause lasting kidney damage and hearing loss respectively 8.
Approximately 85% of people with CF have pancreatic enzyme deficiency due to a
build up of thickened mucus blocking ducts within the pancreas 9. This causes
problems in digestion and adsorption of fats, proteins and fat soluble vitamins (A, D,
E and K) leading to malnutrition, poor growth and failure to thrive, as well as
problems with offensive stools and risk of distal ileal obstruction syndrome (DIOS) 9.
With age, pancreatic disease can lead to decreased insulin production and the
development of diabetes mellitus in up to 50% of adult CF patients 10. Malnutrition,
along with side-effects from steroid medication, also can cause weakened bones,
leading to the development of osteoporosis 11. Joint problems and arthritis are also
prevalent in those with CF 12.
Between 25-40% of people with CF suffer from upper respiratory tract problems of
rhinosinusitis and nasal polyps 13. Approximately 30% of patients with CF have
disease involving their liver ducts 14. This can lead to cirrhosis and portal
hypertension with a requirement for liver transplant in some. Most males with CF are
infertile due to blockage of the vas deferens 15. Female fertility is not directly affected
by the CFTR mutation, but the effects of low weight and malnutrition can lead to
problems with irregular menstruation 16.
The cumulative effect of these multisystem manifestations is an increase in mortality,
although this is improving year on year, with current best estimate of median survival
being greater than 50 years for those born in the year 2000 17. The treatment burden
of this chronic condition leads to a huge impact on daily activities and can
significantly affect quality of life. Doctors and other members of the multidisciplinary
team face many treatment decisions in managing this multi-system disorder.
Why identify gaps in the evidence for CF?
CF patients comprise a small population with multifaceted clinical questions to
answer. With finite budgets and resources and limitations in the size of the pool of
eligible patients (10,000 UK, 28,000 US 1,2) to take part in trials, research needs to
be targeted to produce clinically meaningful answers. There is a need for identifying
the knowledge gaps in the treatment of CF and prioritising research areas, so that
limited resources are used appropriately.
Systematic reviews are usually undertaken to identify the evidence for benefit (or
harms) from an intervention, in order to inform guidelines and guide clinical practice.
One example might be the use of prophylactic anti-staphylococcal antibiotics in
young infants with CF. Here the systematic review shows the use of these antibiotics
is associated with fewer infections with Staphylococcus aureus but identifies a
potential harm from a trend towards more frequent infections with Pseudomonas
aeruginosa18. So systematic reviews may identify the “known knowns”. However, this
approach may also be used to highlight the interventions where there is no evidence
to guide the use of a therapy. One example is physical training in people with CF19
where few trials have been done and those that have are small and underpowered.
These “known unknowns” are areas where systematic reviews have shown there is a
need for clinical trials. However, the number of such questions will far exceed the
capacity of the research community, the funding available for CF research and the
number of eligible participants with CF. For this reason, prioritisation is needed. This
prioritisation should be done in partnership with patients (who will be asked to
participate in trials and who might benefit from the findings), clinicians (who deliver
therapies) and healthcare commissioners (who will have to pay for any future
innovations). In the UK, a model for such a consultation exercise has been
proposed, termed a James Lind Alliance Priority Setting Partnership (JLA PSP)20.
This is now supported by the National Institute for Health Research (NIHR). For
prioritisation to be useful, it must start with the true gaps in the evidence.
Description of the interventions
Due to the multi-system nature of the disease, interventions are also numerous and
are targeted at different aspects of the condition. The range of treatments and their
interaction with different manifestations of the disease are described in a conceptual
framework (Figure 1).
Potential impact of this review
Presently the direction of clinical research is guided by researchers choosing topics
that are fashionable, of personal interest or, commonly, of interest to funders
including the pharmaceutical industry. We aim to use this review to create an up to
date list of treatment uncertainties in the field of cystic fibrosis with the reason for
uncertainty (e.g. insufficient information, biased information or inconsistency 21).
Identified gaps in the evidence can then be used as a resource to guide both
researchers and funding bodies to focus the approach of research in treatment
decisions in cystic fibrosis to ensure important areas are not missed. This review
could be used to identify priority areas for systematic review and be used as a base
for a priority setting exercise with clinicians, patients, families and other interested
parties, for example, in collaboration with the James Lind Alliance. It may also be
helpful to commissioners by contributing towards a health needs assessment.
Through reviewing evidence gaps we will identify clinically relevant outcome
measures which can be used as a starting point for developing a common outcome
set for CF.
Objectives
To conduct an overview of systematic reviews and CF guidelines to identify
 Gaps in evidence for treatment of CF.
 Why the gaps exist.
 Ways in which the gaps can be addressed.
Methods
Criteria for considering studies for this review
Types of reviews
All systematic reviews published in English that meet our selection criteria. Reviews
have to fulfil The Cochrane Collaboration's definition of a systematic review -
‘reviews of clearly formulated questions that use systematic and explicit methods to
identify, select and critically appraise relevant research, and to collect and analyse
data from the studies included in the reviews’ 22. The ROBIS tool will be used to
assess risk of bias and quality of non-Cochrane reviews 23. Only reviews deemed to
be at low risk of bias will be included in our analysis. Several studies have deemed
that Cochrane reviews are of a very high quality so we intend to accept these
reviews without assessing risk of bias and quality 24,25.
We will include systematic reviews of randomised controlled trials, other study types
and qualitative systematic reviews.
We will also search for reviews that are still at the protocol stage to help identify
whether treatment uncertainties that we find are likely to be addressed in the near
future.
We will also include evidence-based clinical guidelines published in the past 10
years that meet our inclusion criteria.
Types of participants
Participants will be those diagnosed with Cystic Fibrosis (through genetic testing or
sweat testing) of any age and in both inpatient and outpatient settings. Those
patients who are screen positive but with no firm diagnosis will be excluded. Reviews
including other conditions but where CF patients are analysed as a specific subgroup
will be included providing they meet the rest of the inclusion criteria.
Types of interventions
We will include systematic reviews of treatment interventions in CF. Scope of
interventions are categorised in the conceptual framework shown in figure 1. We will
exclude reviews covering diagnosis, newborn screening or those concerning
diagnostic test accuracy as these do not fall under our definition of treatments. We
will also exclude those concerning policy, evaluation of the training of physicians or
organisation of care (e.g. specialist CF clinics versus general clinic care). However
we will consider systematic reviews including trials of timings and duration of
intervention, combinations of interventions and stopping interventions.
Types of outcome measures
We will capture a variety of outcome measures. We aim to seek those that are
clinically meaningful and confer or reflect patient benefit. Using the framework in
figure 2, outcomes will be categorised by treatment and by organ system. We expect
that the outcomes will fall into the broad categories listed below. We hope that this
process will capture a variety of outcome measures and may help with a future
initiative to identify core outcome sets in CF.
 Lung Function (e.g. FEV1,FVC, FEF25-75, PEFR, measures of bronchial
hyperresponsiveness, trough FEV1, Lung clearance index)
 Health-related quality of life validated measures (e.g. Cystic Fibrosis
Questionnaire (CFQ) 26)
 Respiratory symptom outcomes (e.g. Respiratory and Systemic Symptoms
Questionnaire RSSQ, Respiratory Symptom Questionnaire RSQ 27)
 Hospitalisation (e.g. number of nights inpatient per year)
 School/Work attendance (e.g. number of days missed)
 Nutrition & Growth (e.g. weight gain, height, fat)
 Radiological (e.g. bone mineral density)
 Microbiological (e.g. sputum culture growth)
 Pulmonary exacerbations, as measured by frequency of exacerbation or time
to next exacerbation. A pulmonary exacerbation must be clearly defined in the
included review.
 CF related mortality
 Antibiotic use (e.g. number of courses, delivery method)
 Steroid use
 Adverse effects (toxicity & allergy, microbiology, complication of delivery)
 Exercise tolerance
 Sweat chloride as a measure of CFTR function
 Mucus clearance
 Lab markers (e.g. antibody levels, immunology responses, organ function
tests, vitamin levels, blood glucose levels)
 Nasal symptom scores (validated)
 Bowel symptoms (e.g. stool frequency, abdominal pain)
 Audiology
 Need for surgery (e.g. Transplant, polyp removal)
 Need for further procedure
 Burden of treatment (using validated measure)
 Treatment adherence
 Cost
Search methods
The review authors will identify relevant reviews by searching the Cochrane
database of reviews in CF.
Non-Cochrane systematic reviews in CF will be searched for using EMBASE,
MEDLINE, CINAHL and PubMed. Search strategies will be devised iteratively and
search terms will be kept broad to increase sensitivity. Pre-defined search strategies
designed to identify systematic reviews have been used in MEDLINE, EMBASE and
CINAHL 28 See search strategies in appendix A.
Clinical guidelines published in the last ten years will be identified by searching the
following guideline repositories: CF Trust; CF Foundation; European Cystic Fibrosis
Society (ECFS); National Institute for Health and Care Excellence (NICE); National
Guidelines Clearing House; Cystic Fibrosis Federation Australia
Unpublished systematic reviews appearing in the grey literature will be identified via
the Opengrey website.
Additional research gaps and uncertainties not yet covered by systematic review will
be searched for in DUETS and clinical trials registers (clinicaltrials.gov, ISRCTN).
Protocols will be searched for in PROSPERO and the Cochrane library.
Search results will be downloaded to Endnote (vX7) and checked for duplicates
using the inbuilt duplicate finder and a manual check will also be carried out. Titles
and abstracts will be scanned by two reviewers.
Data collection and analysis
Selection of studies
Titles and abstracts will be scanned by two reviewers (one clinical, one a
methodologist) against the inclusion criteria and those not relevant will be excluded.
Where there is disagreement between reviewers, a third reviewer will arbitrate.
Systematic reviews which are deemed to meet the inclusion criteria will be retrieved
in full and scanned again for inclusion. At this stage we will record a reason for
exclusion for the papers we do not include.
We will accept Cochrane reviews which meet our general inclusion criteria. We will
apply quality criteria to non-Cochrane reviews using the ROBIS tool23. Two reviewers
will assess the risk of bias and any discrepancies or with risk unclear will be
discussed. A third reviewer will arbitrate if necessary. Those deemed to be at high
risk of bias will be excluded.
This process is shown as a flow diagram in Appendix B.
Data extraction and management
Two reviewers will extract data from all included reviews using a pre-defined, pre-
piloted data extraction form adapted from “Framework for Determining Research
Gaps During Systematic Review” 21. We will lump gaps together rather than split
them to make it a useable document for clinicians/patients.
Data items will include:
 The identified gap in the evidence
 Reason for the gap
 Population studied
 Intervention studied
 Comparator
 Outcomes measured
 Setting
Any discrepancies in data extraction will be passed to a third reviewer for a decision
to be made.
Guidelines and protocols
Guidelines and protocols will be searched as a separate exercise by two reviewers.
Relevant guidelines will be included in the data extraction process. A list of relevant
protocols will be created (from the Cochrane Library and PROSPERO) by two
reviewers and compared. Once a final list has been agreed, this will be used as a
reference to highlight where identified evidence gaps are being addressed.
Analysis
Data will be collated using Excel. We will then identify themes and compile a table of
known treatment uncertainties in CF, reason for these uncertainties and how they
may be addressed. Descriptive statistics will be used to describe the data. If there
are areas with more gaps that others, for example Gastrointestinal versus
Respiratory, we may use simple statistical tests such as Chi squared to analyse
significance.
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Figure 1.Framework of systems involved and treatment interventions in CF
Figure 2. Framework of outcomes in CF
Appendix A. Search Strategies
COCHRANE LIBRARY
‘cystic fibrosis’ in Title, Abstract, Keywords in Cochrane Reviews
The standardised SIGN search criteria are used for Medline, Embase and CINAHL
to search for systematic reviews
MEDLINE
1. Meta-Analysis as Topic/
2. meta analy$.tw.
3. metaanaly$.tw.
4. Meta-Analysis/
5. (systematic adj (review$1 or overview$1)).tw.
6. exp Review Literature as Topic/
7. or/1-6
8. cochrane.ab.
9. embase.ab.
10. (psychlit or psyclit).ab.
11. (psychinfo or psycinfo).ab.
12. (cinahl or cinhal).ab.
13. science citation index.ab.
14. bids.ab.
15. cancerlit.ab.
16. or/8-15
17. reference list$.ab.
18. bibliograph$.ab.
19. hand-search$.ab.
20. relevant journals.ab.
21. manual search$.ab.
22. or/17-21
23. selection criteria.ab.
24. data extraction.ab.
25. 23 or 24
26. Review/
27. 25 and 26
28. Comment/
29. Letter/
30. Editorial/
31. animal/
32. human/
33. 31 not (31 and 32)
34. or/28-30,33
35. 7 or 16 or 22 or 27
36. 35 not 34
37. exp Cystic Fibrosis/
38. cystic fibrosis.tw.
39. fibrocystic near disease near pancreas.tw.
40. mucoviscidos$.tw.
41. (cystic$ adj10 fibros$).tw.
42. or/37-41
43. 36 and 42
EMBASE
1. exp Meta Analysis/
2. ((meta adj analy$) or metaanalys$).tw.
3. (systematic adj (review$1 or overview$1)).tw.
4. or/1-3
5. cancerlit.ab.
6. cochrane.ab.
7. embase.ab.
8. (psychlit or psyclit).ab.
9. (psychinfo or psycinfo).ab.
10. (cinahl or cinhal).ab.
11. science citation index.ab.
12. bids.ab.
13. or/5-12
14. reference lists.ab.
15. bibliograph$.ab.
16. hand-search$.ab.
17. manual search$.ab.
18. relevant journals.ab.
19. or/14-18
20. data extraction.ab.
21. selection criteria.ab.
22. 20 or 21
23. review.pt.
24. 22 and 23
25. letter.pt.
26. editorial.pt.
27. animal/
28. human/
29. 27 not (27 and 28)
30. or/25-26,29
31. 4 or 13 or 19 or 24
32. 31 not 30
33. exp cystic fibrosis/
34. cystic fibrosis.tw.
35. fibrocystic disease.tw.
36. mucoviscidos$.tw.
37. (cystic$ adj10 fibros$).tw.
38. or/33-37
39. 32 and 38
PUBMED
#1 (((systematic review[Title] OR systematic review[Text Word]) OR meta-
analysis[Title]) OR meta-analysis[Text Word])
#2 ("cystic fibrosis"[MeSH Terms] OR ("cystic"[All Fields] AND "fibrosis"[All Fields])
OR "cystic fibrosis"[All Fields]
#3 #1 AND #2
#4 Medline [sb]
#5 #3 NOT #4
PROSPERO
‘Cystic fibrosis’ in all fields
DUETS
‘Cystic fibrosis’
OPEN GREY
‘Cystic fibrosis’ and ‘systematic review’
Limited to English
CINAHL
S10 S8 and S9 182 EditS10
S9 (MH "Cystic Fibrosis") 5,283 EditS9
S8 S1 OR S2 OR S3 OR S4
OR S5 OR S6 OR S7
117,955 EditS8
S7 ""systematic overview*"" 358 EditS7
S6 ""systematic review*"" 57,773 EditS6
S5 ""Literature review*"" 54,494 EditS5
S4 (MH "Literature Review+")
OR (MH "Systematic
Review")
38,828 EditS4
S3 ""meta-analys*"" 35,086 EditS3
S2 "Meta Analysis") "meta
analys*""
198 EditS2
S1 (MH "Meta Analysis") 23,707
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GUIDELINES
National Guideline Clearinghouse
Search terms “cystic fibrosis”
(www.guideline.gov)
NICE
Search terms “cystic fibrosis”
(www.nice.org.uk)
CF Foundation
CF Clinical care guidelines
(https://www.cff.org/Search.aspx?topic=216)
CF Trust
Search on concensus documents
(http://www.cysticfibrosis.org.uk/search?keywords=guidelines&page=2)
ECFS
Searched on clinical guidelines
(https://www.ecfs.eu/ecfs_guidelines)
Cystic Fibrosis Federation Australia
Searched on ‘guidelines’
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Appendix B. Flow diagram of study selection process
